Co-op CARs for targeting acute myeloid leukemia
- PMID: 37832553
- DOI: 10.1016/j.ccell.2023.09.015
Co-op CARs for targeting acute myeloid leukemia
Abstract
Chimeric antigen receptor (CAR) T cell therapies are limited by antigen escape and on-target/off-tumor toxicity. In addressing these challenges, Haubner et al. develop an "IF-BETTER" strategy. Their combinatorial chimeric co-stimulatory receptor with an attenuated CAR enhances acute myeloid leukemia (AML) killing while protecting healthy progenitors, highlighting the potential to leverage cooperative CAR designs.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Cooperative CAR targeting to selectively eliminate AML and minimize escape.Cancer Cell. 2023 Nov 13;41(11):1871-1891.e6. doi: 10.1016/j.ccell.2023.09.010. Epub 2023 Oct 5. Cancer Cell. 2023. PMID: 37802054 Free PMC article.